MR. ANTHONY INTERRANTE III NP
Prescription History 1669950739
Nurse Practitioner - Adult Health in Phoenix, AZ

NPI Status: Active since August 01, 2018

Contact Information

3308 N 28TH ST
PHOENIX, AZ
ZIP 85016
Phone: (215) 872-9575
Fax: (404) 585-2688

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MR. ANTHONY INTERRANTE III NP, an active Adult Health specialist practicing in Phoenix, AZ. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 823 documented patient claims. Among these therapy options, the most frequently utilized medication is Descovy, which accounts for 666 claims alone.

Medication Index

No matching medications currently found on file.

Descovy

Generic Formulation: Emtricitabine/Tenofov AlafenamSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 666
30-Day Fills 666.0
Days Supply 19,980
AZ State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills55.4
Peer Average Days Supply1,661
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 1,156.6% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,521,370.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,284.34

State Avg Cost Per Claim

$2,211.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir alafenamide. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Use combination treatment with at least one other HIV medication. This product is also approved in the US to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 36
30-Day Fills 38.0
Days Supply 881
AZ State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.4
Peer Average Days Supply464
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,929.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$53.60

State Avg Cost Per Claim

$22.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Emtricitabine-Tenofovir Disop

Generic Formulation: Emtricitabine/Tenofovir (Tdf)Specialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 121
30-Day Fills 121.0
Days Supply 3,630
AZ State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.7
Peer Average Days Supply498
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 656.3% higher than the standard regional baseline profile for AZ. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,324.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$151.44

State Avg Cost Per Claim

$311.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of emtricitabine and tenofovir that is used as an ANTI-HIV AGENT in the treatment and prevention of HIV INFECTIONS.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Combination treatment with at least one other HIV medication should be used. This product is also used to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MR. ANTHONY INTERRANTE III NP provides transparency into local medical care patterns within Phoenix, AZ.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Adult Health** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.